Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised... by Kristeleit, Rebecca, MD, Lisyanskaya, Alla, MD, Fedenko, Alexander, MD, Dvorkin, Mikhail, MD, de Melo, Andreia Cristina, MD, Shparyk, Yaroslav, Prof, Rakhmatullina, Irina, Prof, Bondarenko, Igor, Prof, Colombo, Nicoletta, Prof, Svintsitskiy, Valentyn, MD, Biela, Luciano, MD, Nechaeva, Marina, MD, Lorusso, Domenica, Prof, Scambia, Giovanni, Prof, Cibula, David, MD, Póka, Róbert, Prof, Oaknin, Ana, MD, Safra, Tamar, MD, Mackowiak-Matejczyk, Beata, MD, Ma, Ling, MD, Thomas, Daleen, BSc, Lin, Kevin K, PhD, McLachlan, Karen, PhD, Goble, Sandra, MSc, Oza, Amit M, Prof

Get full text

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 10... by Monk, Bradley J, Prof, Colombo, Nicoletta, MD, Oza, Amit M, Prof, Fujiwara, Keiichi, Prof, Birrer, Michael J, Prof, Randall, Leslie, Prof, Poddubskaya, Elena V, MD, Scambia, Giovanni, Prof, Shparyk, Yaroslav V, MD, Lim, Myong Cheol, MD, Bhoola, Snehalkumar M, MD, Sohn, Joohyuk, Prof, Yonemori, Kan, MD, Stewart, Ross A, PhD, Zhang, Xiaoxi, PhD, Perkins Smith, Julia, MD, Linn, Carlos, MD, Ledermann, Jonathan A, Prof

Get full text

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial by Robertson, John F R, Prof, Bondarenko, Igor M, Prof, Trishkina, Ekaterina, PhD, Dvorkin, Mikhail, MD, Panasci, Lawrence, Prof, Manikhas, Alexey, MD, Shparyk, Yaroslav, PhD, Cardona-Huerta, Servando, PhD, Cheung, Kwok-Leung, MD, Philco-Salas, Manuel Jesus, MD, Ruiz-Borrego, Manuel, MD, Shao, Zhimin, Prof, Noguchi, Shinzaburo, Prof, Rowbottom, Jacqui, MSc, Stuart, Mary, MD, Grinsted, Lynda M, MSc, Fazal, Mehdi, MD, Ellis, Matthew J, Prof

Get full text

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial by Diéras, Véronique, MD, Han, Hyo S, MD, Kaufman, Bella, MD, Wildiers, Hans, Prof, Friedlander, Michael, Prof, Ayoub, Jean-Pierre, MD, Puhalla, Shannon L, MD, Bondarenko, Igor, Prof, Campone, Mario, Prof, Jakobsen, Erik H, MD, Jalving, Mathilde, MD, Oprean, Cristina, MD, Palácová, Marketa, MD, Park, Yeon Hee, MD, Shparyk, Yaroslav, MD, Yañez, Eduardo, MD, Khandelwal, Nikhil, PhD, Kundu, Madan G, PhD, Dudley, Matthew, PhD, Ratajczak, Christine K, PhD, Maag, David, PhD, Arun, Banu K, Prof

Get full text

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, ad... by Finn, Richard S, MD, Crown, John P, Prof, Lang, Istvan, MD, Boer, Katalin, MD, Bondarenko, Igor M, Prof, Kulyk, Sergey O, MD, Ettl, Johannes, MD, Patel, Ravindranath, MD, Pinter, Tamas, MD, Schmidt, Marcus, MD, Shparyk, Yaroslav, MD, Thummala, Anu R, MD, Voytko, Nataliya L, MD, Fowst, Camilla, MD, Huang, Xin, PhD, Kim, Sindy T, BS, Randolph, Sophia, MD, Slamon, Dennis J, Prof

Get full text